Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771 · 1 trial · 1 indication
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| Arm | Type | Description |
|---|---|---|
| Active tratment | EXPERIMENTAL | Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771 |
| Name | Type | Description |
|---|---|---|
| Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771 | DRUG | PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years; * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs); Exclusion Criteria: * Any condition possibly affecting drug absorption * History of regular alcohol consumption ...
PF-05089771 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 drug-drug interaction trial in healthy adult volunteers in Belgium. The compound is a small molecule and its therapeutic area is classified as other, with no disclosed indication.
PF-05089771 targets HMGCR, also known as HMG-CoA reductase, and acts as an inhibitor of that target. HMGCR is the enzyme targeted by statin medicines. The drug is a small molecule inhibitor, and this target information is recorded under ChEMBL identifier CHEMBL1144.
PF-05089771 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical work recorded for this compound, including the Phase 1 drug-drug interaction study conducted in healthy volunteers.
PF-05089771 is in Phase 1 clinical development. It is an investigational drug and is not described as approved. One Phase 1 trial has been completed, and no trials are currently listed as active.
PF-05089771 has been studied in one completed Phase 1 trial, NCT01934569, titled Drug-Drug Interaction Study With PF-05089771. That trial enrolled 17 healthy adult volunteers of all sexes, aged 18 years and older, in Belgium. It was an uncontrolled study without randomization or double blinding.
PF-05089771 has been evaluated alongside pravastatin, midazolam, losartan, omeprazole and caffeine in a completed Phase 1 drug-drug interaction study, NCT01934569, conducted in healthy volunteers in Belgium. That trial enrolled 17 participants and was designed to assess interactions between these agents.